Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c

Molecular Medicine Reports

Volumn 6, Issue 4, 2012, Pages 815-820

  Zhang, Jingming ^a   Tan, Yingying ^a   Yao, Fanrong ^b   Zhang, Qi ^a  

^a SHAANXI UNIVERSITY OF CHINESE MEDICINE   (China)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Fatty liver; Hepatic steatosis; Polydatin; Sterol regulatory element binding protein; Tumor necrosis factor

Indexed keywords

ACYL COENZYME A DESATURASE 1; CHOLESTEROL; FATTY ACID; FATTY ACID SYNTHASE; LIVER PROTECTIVE AGENT; LIVER PROTEIN; MALONALDEHYDE; MESSENGER RNA; POLYDATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FATTY LIVER; GENE EXPRESSION; LIPID LIVER LEVEL; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOLESTEROL; DIET, HIGH-FAT; FATTY ACID SYNTHASES; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GLUCOSIDES; LIPID PEROXIDATION; LIPOGENESIS; LIVER; MALE; POLYGONUM CUSPIDATUM; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RHIZOME; STEAROYL-COA DESATURASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STILBENES; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865187798     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1015     Document Type: Article

References (42)

1. Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L and Velagić V: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539-4550, 2007. (Pubitemid 47455230)
2. Angulo P: Non-alcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
3. Yeh MM and Brunt EM: Pathology of non-alcoholic fatty liver disease. Am J Clin Pathol 128: 837-847, 2007. (Pubitemid 350133997)
4. Farrell GC and Larter CZ: Non-alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006.
5. Postic C and Girard J: The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 34: 643-648, 2008.
6. Ayyad C and Andersen T: Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 1: 113-119, 2000.
7. Xue L: Progress in the pharmacological study of Chinese herbal drug: Polygonum cuspidatum. Zhongguo Zhong Yao Za Zhi 25: 651-653, 2000.
8. Luper S: A review of plants used in the treatment of liver disease: part two. Altern Med Rev 4: 178-188, 1999.
9. Kimura Y: Pharmacological studies on resveratrol. Methods Find Exp Clin Pharmacol 25: 297-310, 2003.
10. Zhang H, Dou C and Gu F: Advances in the study on pharmacological actions of Polygonum cuspidatum Sieb: clearing heat and detoxication. Zhong Yao Cai 26: 606-610, 2003.
11. Huang ZS, Wang ZW, Liu MP, Zhong SQ, Li QM and Rong XL: Protective effects of polydatin against CCl(4)-induced injury to primarily cultured rat hepatocytes. World J Gastroenterol 5: 41-44, 1999.
12. Ji H, Zhang X, Du Y, Liu H, Li S and Li L: Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull 87: 50-59, 2012.
13. Du J, Sun LN, Xing WW, et al: Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine 16: 652-658, 2009.
14. Xing WW, Wu JZ, Jia M, Du J, Zhang H and Qin LP: Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomed Pharmacother 63: 457-462, 2009.
15. Zhang Q, Zhao Y, Zhang DB and Sun LJ: Effect of Sinai san decoction on the development of non-alcoholic steatohepatitis in rats. World J Gastroenterol 11: 1392-1395, 2005. (Pubitemid 40425928)
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-2474, 1999. (Pubitemid 29420675)
17. Folch J, Lees M, Sloane and Starley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509, 1957.
18. Bartlett GR: Phosphorous assay in column chromatography. J Biol Chem 234: 466-468, 1959.
19. Zhang Q and Tan Y: Nerve growth factor augments neuronal responsiveness to noradrenaline in cultured dorsal root ganglion neurons of rats. Neuroscience 193: 72-79, 2011.
20. Zhang Q, Yao F, Raizada MK, O'Rourke ST and Sun C: Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res 104: 1421-1428, 2009.
21. Diehl AM, Li ZP, Lin HZ and Yang SQ: Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54: 303-306, 2005. (Pubitemid 40139250)
22. Tilg H and Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343: 1467-1476, 2000.
23. Crespo J, Cayon A, Fernandez-Gil P, et al: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34: 1158-1163, 2001. (Pubitemid 33096588)
24. Abiru S, Migita K, Maeda Y, et al: Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26: 39-45, 2006.
25. Poniachik J, Csendes A, Diaz JC, et al: Increased production of IL-1alpha and TNFalpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 33: 252-257, 2006.
26. Tomita K, Tamiya G, Ando S, et al: Tumour necrosis factor alpha signaling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55: 415-424, 2006. (Pubitemid 43268283)
27. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A and George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin. Hepatology 40: 46-54, 2004. (Pubitemid 38868922)
28. Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G and Fuggetta MP: Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation 35: 240-248, 2012.
29. Wang X, Song R, Bian HN, Brunk UT, Zhao M and Zhao KS: Polydatin protects arterial smooth muscle cells against mitochondrial dysfunction and lysosomal destabilization following hemorrhagic shock. Am J Physiol Regul Integr Comp Physiol: Jan 25, 2002 (Epub ahead of print).
30. Shimano H: Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res 40: 439-452, 2001.
31. Raghow R, Yellaturu C, Deng X, Park EA and Elam MB: SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 19: 65-73, 2008. (Pubitemid 351317897)
32. Yan D, Lehto M, Rasilainen L, et al: Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis. Arterioscler Thromb Vasc Biol 27: 1108-1114, 2007. (Pubitemid 46641966)
33. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T and Yoshikawa T: Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277: 19353-19357, 2002. (Pubitemid 34967441)
34. Shimomura I, Bashmakov Y and Horton JD: Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274: 30028-30032, 1999.
35. Ahmed MH and Byrne CD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 12: 740-747, 2007. (Pubitemid 47362786)
36. Ntambi JM, Miyazaki M, Stoehr JP, et al: Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99: 11482-11486, 2002. (Pubitemid 34920951)
37. Shrestha S, Ehlers SJ, Lee JY, Fernandez ML and Koo SI: Dietary green tea extract lowers plasma and hepatic triglycerides and decreases the expression of sterol regulatory element-binding protein-1c mRNA and its responsive genes in fructose-fed, ovariectomized rats. J Nutr 139: 640-645, 2009.
38. Saltiel A and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001. (Pubitemid 34000783)
39. Browning J and Horton J: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152, 2004. (Pubitemid 39071617)
40. Utzschneider KM and Kahn SE: Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91: 4753-4761, 2006. (Pubitemid 44917301)
41. Previs SF, Withers DJ, Ren JM, White MF and Shulman GI: Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 275: 38990-38994, 2000. (Pubitemid 32058910)
42. Samuel VT, Liu ZX, Qu X, et al: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279: 32345-32353, 2004. (Pubitemid 39014687)